Dyne Q1 net loss $115.4M ($1.05/sh); advances DM1 & DMD toward 2026-2027 approvals

Dyne Therapeutics, Inc.

2025-Q1 EPS reported -$1.05

Cash $677.5M; expects funding operations into H2 2026.
R&D expenses $106.4M (Q1 2025) vs $44.5M (Q1 2024); net loss widened.
ACHIEVE Registrational Expansion Cohort for DYNE-101 (DM1) initiated; up to 48 patients; data H1 2026.
DELIVER Registrational Expansion Cohort for DYNE-251 (DMD) fully enrolled (32 patients); data late 2025.
New CFO (Erick Lucera), CBO (Vikram Ranade), CSO (Ranjan Batra); Oxana Beskrovnaya named CIO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.